The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
36056582
PubMed Central
PMC10092332
DOI
10.1002/ijc.34275
Knihovny.cz E-resources
- Keywords
- DNA methylation, abnormal vaginal bleeding, cervical cancer, early detection, endometrial cancer,
- MeSH
- Cytodiagnosis MeSH
- Uterine Hemorrhage diagnosis pathology MeSH
- Uterine Cervical Dysplasia * diagnosis MeSH
- Endometrium pathology MeSH
- Papillomavirus Infections * diagnosis MeSH
- Humans MeSH
- Uterine Cervical Neoplasms * diagnosis genetics pathology MeSH
- Sensitivity and Specificity MeSH
- Feasibility Studies MeSH
- Vaginal Smears MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The majority of endometrial and cervical cancers present with abnormal vaginal bleeding but only a small proportion of women suffering from vaginal bleeding actually have such a cancer. A simple, operator-independent and accurate test to correctly identify women presenting with abnormal bleeding as a consequence of endometrial or cervical cancer is urgently required. We have recently developed and validated the WID-qEC test, which assesses DNA methylation of ZSCAN12 and GYPC via real-time PCR, to triage women with symptoms suggestive of endometrial cancer using ThinPrep-based liquid cytology samples. Here, we investigated whether the WID-qEC test can additionally identify women with cervical cancer. Moreover, we evaluate the test's applicability in a SurePath-based hospital-cohort by comparing its ability to detect endometrial and cervical cancer to cytology. In a set of 23 cervical cancer cases and 28 matched controls the receiver operating characteristic (ROC) area under the curve (AUC) is 0.99 (95% confidence interval [CI]: 0.97-1.00) with a sensitivity and specificity of 100% and 92.9%, respectively. Amongst the hospital-cohort (n = 330), the ROC AUC is 0.99 (95% CI: 0.98-1) with a sensitivity and specificity of 100% and 82.5% for the WID-qEC test, respectively, and 33.3% and 96.9% for cytology (considering PAP IV/V as positive). Our data suggest that the WID-qEC test detects both endometrial and cervical cancer with high accuracy.
Danube Private University Krems an der Donau Austria
Department of Gynecology and Obstetrics General Hospital Hall Tirol Kliniken Hall in Tirol Austria
Department of Women's and Children's Health Karolinska Institutet Stockholm Sweden
Institute for Biomedical Aging Research Universität Innsbruck Innsbruck Austria
See more in PubMed
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913‐2921. PubMed
Lortet‐Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978‐2013. J Natl Cancer Inst. 2018;110:354‐361. PubMed
Pennant ME, Mehta R, Moody P, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017;124:404‐411. PubMed PMC
Clarke MA, Long BJ, Del Mar MA, Arbyn M, Bakkum‐Gamez JN, Wentzensen N. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta‐analysis. JAMA Intern Med. 2018;178:1210‐1222. PubMed PMC
Frias‐Gomez J, Benavente Y, Ponce J, et al. Sensitivity of cervico‐vaginal cytology in endometrial carcinoma: a systematic review and meta‐analysis. Cancer Cytopathol. 2020;128:792‐802. PubMed
Frias‐Gomez J, Tovar E, Vidal A, et al. Sensitivity of cervical cytology in endometrial cancer detection in a tertiary hospital in Spain. Cancer Med. 2021;10:6762‐6766. PubMed PMC
Bruni L, Serrano B, Roura E, et al. Cervical cancer screening programmes and age‐specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10:e1115‐e1127. PubMed PMC
Rozemeijer K, Naber SK, Penning C, et al. Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. BMJ. 2017;356:j504. PubMed PMC
Herzog C, Marín F, Jones A, et al. A simple cervico‐vaginal epigenetic test for early endometrial cancer detection: validation in several cohort and case/control sets. J Clin Oncol. 2022. doi:10.1200/JCO.22.00266 PubMed DOI PMC
Barrett JE, Herzog C, Jones A, et al. The WID‐BC‐index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nat Commun. 2022;13:449. PubMed PMC
Barrett JE, Jones A, Evans I, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nat Commun. 2022;13:448. PubMed PMC
